Development of a preventive vaccine for Ebola virus infection in primates

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Nature

• Publication date

  2000-11-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/35046108PMID 11117750
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epitopes involved in antibody-mediated protection from Ebola virus.

  2000cited by this paper
• Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients

  1999cited by this paper
• Molecular Medicine © 1999 The Picower Institute Press Efficient Generation of Recombinant Adenoviral Vectors by Cre-lox Recombination In Vitro

  1999cited by this paper
• Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection

  1999cited by this paper
• Pathogenesis of experimental Ebola virus infection in guinea pigs.

  1999cited by this paper
• Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant.

  1999cited by this paper
• Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

  1999cited by this paper
• DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge.

  1998cited by this paper
• A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

  1998cited by this paper
• A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

  1998cited by this paper
• Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine.

  1998cited by this paper
• Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

  1998cited by this paper
• Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime.

  1998cited by this paper
• Immunization for Ebola virus infection

  1998cited by this paper
• Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination.

  1997cited by this paper
• Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization

  1996cited by this paper
• A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.

  1996cited by this paper
• The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing.

  1996cited by this paper
• CpG motifs in bacterial DNA trigger direct B-cell activation

  1995cited by this paper
• Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein.

  1994cited by this paper
• Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein.

  1994cited by this paper
• Gene therapy for vascular smooth muscle cell proliferation after arterial injury.

  1994cited by this paper
• Gene inoculation generates immune responses against human immunodeficiency virus type 1.

  1993cited by this paper
• Heterologous protection against influenza by injection of DNA encoding a viral protein.

  1993cited by this paper
• Genetic immunization is a simple method for eliciting an immune response

  1992cited by this paper
• Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates

  1992cited by this paper
• Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.

  1992cited by this paper
• Expression of hepatitis B surface antigen with a recombinant adenovirus.

  1985cited by this paper
• Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola).

  1985cited by this paper
• Ebola virus: identification of virion structural proteins.

  1980cited by this paper

• Public sector innovation and the constraints of 'platform thinking': An account of Johnson & Johnson's adenoviral vector vaccines.

  2025cites this paper
• Artificial neural network-driven modeling of Ebola transmission dynamics with delays and disability outcomes

  2025cites this paper
• A sustainable method for analyzing and studying the fractional-order panic spreading caused by the COVID-19 pandemic

  2025cites this paper
• Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials

  2025cites this paper
• Recombinant live attenuated measles virus-based vaccines inducing comprehensive protection against Ebola and Marburg viruses.

  2025cites this paper
• Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses.

  2025cites this paper
• Application of CRISPR-Cas System in Pathogenic Microorganism Detection

  2024cites this paper
• Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control

  2024cites this paper
• Computational and stability analysis of Ebola virus epidemic model with piecewise hybrid fractional operator

  2024cites this paper
• An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses

  2024cites this paper
• Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections

  2024cites this paper
• A Single-shot ChAd3 Vaccine Provides Protection from Intramuscular and Aerosol Sudan Virus Exposure

  2024cites this paper
• Clinical and immunological correlates of vasodilatory shock among Ebola virus infected nonhuman primates in a critical care model.

  2023cites this paper
• Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.

  2023cites this paper
• Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

  2023cites this paper
• Ebola et la maladie à filovirus : enjeux et perspectives à l’horizon 2030

  2023cites this paper
• The potential epidemic threat of Ebola virus and the development of a preventive vaccine

  2023cites this paper
• Utilizing non‐human primate models to combat recent COVID‐19/SARS‐CoV‐2 and viral infectious disease outbreaks

  2023influential citation
• Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges

  2023cites this paper
• Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications

  2023cites this paper
• Plant-made vaccines against viral diseases in humans and farm animals

  2023cites this paper
• Epidemiological Analysis of Symmetry in Transmission of the Ebola Virus with Power Law Kernel

  2023cites this paper
• AAV-monoclonal antibody expression protects mice from Ebola virus without impeding the endogenous antibody response to heterologous challenge

  2022cites this paper
• Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels

  2022cites this paper
• Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein

  2022cites this paper
• A Comprehensive Review on COVID-19: Emphasis on Current Vaccination and Nanotechnology Aspects.

  2022cites this paper
• Filoviruses: modern solutions to life-threatening infections

  2022cites this paper
• International Journal of Public Health Science (IJPHS)

  2022cites this paper
• Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens

  2022cites this paper
• Natural History of Sudan ebolavirus to Support Medical Countermeasure Development

  2022influential citation
• A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates

  2022cites this paper
• Plant-Derived Recombinant Vaccines against Zoonotic Viruses

  2022cites this paper
• Plant-based vaccine research development against viral diseases with emphasis on Ebola virus disease: A review study.

  2021cites this paper
• Mining of Ebola virus genome for the construction of multi-epitope vaccine to combat its infection

  2021cites this paper
• Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production

  2021cites this paper
• Ebola Virus Disease, Diagnostics and Therapeutics: Where is the Consensus in Over Three Decades of Clinical Research?

  2021cites this paper
• Rapid and Durable Protection Against Marburg Virus with a Single-Shot ChAd3-MARV GP Vaccine

  2021cites this paper
• CD8 T Cell Vaccines and a Cytomegalovirus-Based Vector Approach

  2021cites this paper
• The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines

  2021cites this paper
• Heterologous prime-boost regimens with HAdV-5 and NDV vectors elicit stronger immune responses to Ebola virus than homologous regimens in mice

  2021cites this paper
• Label‐Free Cell Viability Assay and Enrichment of Cryopreserved Cells Using Microfluidic Cytometry and On‐Demand Sorting

  2021cites this paper
• Immunological mechanisms associated with clinical features of Ebola virus disease and its control and prevention

  2021cites this paper
• Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties

  2021influential citation
• Mapping the global research output on Ebola vaccine from research indexed in web of science and scopus: a comprehensive bibliometric analysis

  2021cites this paper
• CRISPR-Cas systems: From gene scissors to programmable biosensors

  2021cites this paper
• Response of gene regulatory networks after infection of H3N2 virus

  2021cites this paper
• Ebolavirus: Infection, Vaccination and Control

  2021cites this paper
• Global Outbreaks of Ebola Virus Disease and Its Preventive Strategies

  2021cites this paper
• Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection

  2021cites this paper
• Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates

  2021cites this paper
• SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus

  2021cites this paper
• Application of Nanotechnology in the COVID-19 Pandemic

  2021cites this paper
• Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease

  2020cites this paper
• Nano-based approaches in the development of antiviral agents and vaccines

  2020cites this paper
• A Bivalent Human Adenovirus Type 5 Vaccine Expressing the Rabies Virus Glycoprotein and Canine Distemper Virus Hemagglutinin Protein Confers Protective Immunity in Mice and Foxes

  2020cites this paper
• A fractional order model for Ebola Virus with the new Caputo fractional derivative without singular kernel

  2020cites this paper
• The development of gene-based vectors for immunization

  2020cites this paper
• Ebola Virus Dose Response Model for Aerosolized Exposures: Insights from Primate Data

  2020influential citation
• A track-regenerated DNA walker: Construction and its derived sensing application

  2020cites this paper
• Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.

  2020cites this paper
• An effective CTL peptide vaccine for Ebola Zaire Based on Survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design

  2020cites this paper
• Cancer Associated Endogenous Retroviruses: Ideal Immune Targets for Adenovirus-Based Immunotherapy

  2020cites this paper
• Exploiting the Reverse Vaccinology Approach to Design Novel Subunit Vaccine against Ebola Virus

  2020cites this paper
• A Global Perspective on Vaccines: Priorities, Challenges and Online Information

  2020influential citation
• Vaccine Development and Immunological Aspects of Ebola Virus Disease (EVD): An Update

  2020cites this paper
• A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses

  2020cites this paper
• Ethics of Conducting Clinical Research in an Outbreak Setting.

  2020cites this paper
• Ebola and Marburg Virus: A Brief Review

  2020cites this paper
• Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases

  2020cites this paper
• Chapter 4 Adenoviral Vector-Based Vaccines and Gene Therapies : Current Status and Future Prospects

  2019cites this paper
• Identification of novel HLA-A11-restricted T-cell epitopes in the Ebola virus nucleoprotein.

  2019cites this paper
• Recurrent Ebolavirus disease in the Democratic Republic of Congo: update and challenges

  2019cites this paper
• Ebola virus disease: An emerging and re-emerging viral threat.

  2019cites this paper
• On the Regional Control of a Reaction–Diffusion System SIR

  2019cites this paper
• Current Ebola Virus Vaccine Progress

  2019cites this paper
• Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates

  2019cites this paper
• Seroprevalence of Human Adenovirus Type 5 Neutralizing Antibody in Common Marmosets Determined by a New Set of Two Assays

  2019cites this paper
• Ebola vaccine innovation: a case study of pseudoscapes in global health

  2019cites this paper
• Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry

  2019cites this paper
• Moral, ethical and human rights arguments for using experimental and clinically unproven drugs to combat the Ebola Virus Disease

  2019cites this paper
• Ebola Virus: Pathogenesis and Countermeasure Development.

  2019cites this paper
• Comparing Semiconductor Nanocrystal Toxicity in Pregnant Mice and Non-Human Primates

  2019cites this paper
• Ebola: Lessons on Vaccine Development.

  2018cites this paper
• Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebolavirus Glycoprotein

  2018cites this paper
• Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures.

  2018cites this paper
• New Vaccine Technologies to Combat Outbreak Situations

  2018cites this paper
• Novel cyclo‐peptides inhibit Ebola pseudotyped virus entry by targeting primed GP protein

  2018cites this paper
• Animal models for filovirus infections

  2018cites this paper
• Adenoviral Vector-Based Vaccines and Gene Therapies: Current Status and Future Prospects

  2018cites this paper
• High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test.

  2018cites this paper
• From bench to almost bedside: the long road to a licensed Ebola virus vaccine

  2018cites this paper
• Serologic Evidence of Ebolavirus Infection in a Population With No History of Outbreaks in the Democratic Republic of the Congo

  2018cites this paper
• Evaluating the Performance of Classification Algorithms using Ebola Virus Dataset

  2018cites this paper
• Post-exposure treatments for Ebola and Marburg virus infections

  2018cites this paper
• 20 – Ebola Vaccines

  2018cites this paper
• Non-viral Vector for Muscle-Mediated Gene Therapy

  2018cites this paper
• Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination.

  2018cites this paper
• Pharmacoinformatics-based identification of chemically active molecules against Ebola virus

  2018cites this paper
• Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine

  2018cites this paper
• Animal Models of Ebolavirus Infection.

  2017cites this paper